Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan;
Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, Tokyo, Japan.
Anticancer Res. 2022 Feb;42(2):893-902. doi: 10.21873/anticanres.15547.
BACKGROUND/AIM: We aimed to evaluate pancreatic cancer (PC) with positive peritoneal lavage cytology (CY1) outcomes following a change in adjuvant therapy.
The clinicopathological data of patients with pancreatic adenocarcinoma with CY1 at 14 institutions, between 2007 and 2015, were collected and analyzed.
Of the 124 eligible patients, 114 underwent macroscopically curative resection. Of the 114 patients, 80 (70%) did not have early recurrence and received postoperative chemotherapy that was S-1 in 43 (54%), gemcitabine in 31 (39%), and others in six (7%). The median overall survival was 21.0 months in S-1 and 19.2 in gemcitabine therapy (p=0.23), whereas the median relapse-free survival was 10.2 and 7.1 months (p=0.03), respectively.
Following the change in adjuvant therapy, most PC patients with CY1 who underwent macroscopically curative resection received S-1; however, it was insufficient. Further development of postoperative chemotherapy is required.
背景/目的：我们旨在评估辅助治疗改变后伴有阳性腹膜灌洗细胞学（CY1）结果的胰腺癌（PC）。
收集并分析了 2007 年至 2015 年间 14 个机构的胰腺腺癌伴有 CY1 的患者的临床病理数据。
在 124 名合格的患者中，有 114 名患者接受了宏观根治性切除术。在这 114 名患者中，80 名（70%）没有早期复发，并接受了术后化疗，其中 43 名（54%）接受 S-1 治疗，31 名（39%）接受吉西他滨治疗，6 名（7%）接受其他治疗。S-1 治疗组的中位总生存期为 21.0 个月，吉西他滨治疗组为 19.2 个月（p=0.23），而无复发生存期分别为 10.2 和 7.1 个月（p=0.03）。
在辅助治疗改变后，大多数接受宏观根治性切除术且伴有 CY1 的 PC 患者接受了 S-1 治疗；然而，这还不够。需要进一步开发术后化疗。
Zotero 插件